New advances in the diagnosis of von Willebrand disease
Open Access
- 6 December 2019
- journal article
- conference paper
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2019 (1) , 596-600
Abstract
Von Willebrand disease (VWD) is the most common autosomal inherited bleeding disorder, with an estimated prevalence of 1 in 1000 individuals. VWD is classified into quantitative and qualitative forms. Diagnosis of VWD is complex and requires (1) a personal history of bleeding symptoms, (2) family history of bleeding or VWD, and (3) confirmatory laboratory testing. There are certain bleeding assessment tools to objectively measure bleeding symptoms in patients that have been shown to correlate with the diagnosis as well as the severity of VWD. Laboratory diagnosis requires at least initially a measurement of von Willebrand factor (VWF) antigen levels, VWF platelet binding activity (VWF:RCo, VWF:GPIbM, and VWF:GPIbR), and factor VIII (FVIII) activity. Additional testing to confirm the specific subtype may include VWF collagen binding activity, low-dose ristocetin VWF-platelet binding, FVIII-VWF binding, VWF multimer analysis, and VWF propeptide antigen. Recent advances have been made regarding some of these assays. Molecular testing in VWD is not found to be useful in “low VWF” or most type 1 VWD cases but may be informative in patients with severe type 1 VWD, type 1C VWD, type 2 VWD, or type 3 VWD for accurate diagnosis, genetic counseling, and appropriate treatment. The diagnostic algorithm for VWD is complex, but advances continue to be made in improving VWF functional assays and diagnostic pathways.Keywords
This publication has 41 references indexed in Scilit:
- Collagen Binding Provides a Sensitive Screen for Variant von Willebrand DiseaseClinical Chemistry, 2013
- Critical von Willebrand factor A1 domain residues influence type VI collagen bindingJournal of Thrombosis and Haemostasis, 2012
- VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American populationBlood, 2012
- High-throughput molecular diagnosis of von Willebrand disease by next generation sequencing methodsHaematologica, 2012
- Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWDBlood, 2011
- Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactorBlood, 2010
- Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWDJournal of Thrombosis and Haemostasis, 2010
- Clinical and laboratory diagnosis of von Willebrand disease: A synopsis of the 2008 NHLBI/NIH guidelinesAmerican Journal of Hematology, 2009
- Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD)Blood, 2008
- Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survivalBlood, 2006